BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Ekos Raises $18 Million In Series B Financing


10/19/2005 5:12:47 PM

NEW YORK, Feb. 18 /PRNewswire/ -- Funds advised by NGN Capital participated in the financing of a syndicate, along with MedVentures, Morgan Stanley, and EGS Capital in an $18 million Series B financing of EKOS Corporation, located in Bothell, Washington. EKOS is focused on developing and commercializing novel high technology ultrasound-enhanced micro-catheters for dissolving blood clots in the brain or in the peripheral arteries in the legs.

EKOS holds 25 key patents covering the pioneering use of low energy ultrasound catheters to dissolve blood clots in the brain and legs. This advanced minimally invasive technology significantly improves the speed and efficacy of traditional micro-catheters, thereby allowing neurosurgeons, interventional neuroradiologists, interventional radiologists, and vascular surgeons to more quickly and confidently dissolve blood clots. Early clinical data shows that EKOS catheters are capable of opening arteries more often than traditional techniques that are only 50% efficacious.

EKOS catheters are already FDA cleared for peripheral use, where the company is engaged in a series of limited clinical trials in order to further validate the value of its technology. Simultaneously, clinical trials are also underway to further prove the utility in stroke patients. "I am very gratified to have completed this financing round on a timely basis, aided by the efforts of NGN Capital, MedVentures, Morgan Stanley, and EGS Capital. The financing proceeds will be used to provide growth capital for EKOS to expand its marketing and production infrastructure. During the next 18 months, the company expects to double its staff, from 50 to 100 employees," explained Peter Rule, Chairman of EKOS.

Peter Rule, formerly President, CEO, and Chairman of Percusurge, Inc., serves as Chairman and interim CEO of EKOS. Doug Hansmann, co-founder, is the General Manager. The strong pipeline of products will be advanced by a seasoned management team of leading experts in the field of micro-catheters.

Kenneth S. Abramowitz, Managing General Partner, represented NGN Capital as the lead partner in this investment and will hold a board seat. "I am very excited to join the Board of EKOS and look forward to helping guide the company's successful entry into the marketplace."

About EKOS Corporation

EKOS is a privately held high technology medical device company focused on developing and marketing ultrasound enhanced micro-catheters to dissolve blood clots in the brain and legs in conjunction with thrombolytic agents. The company is headquartered in Bothell, Washington and at present has 50 employees.

About NGN Capital

NGN Capital is a global healthcare venture capital investment firm with offices in New York, Heidelberg, Germany and Greenwich, Connecticut. NGN has investment capabilities across all the major segments in healthcare, including pharmaceuticals, biopharmaceuticals, medical devices, diagnostics, and healthcare services.

More information on NGN can be found at http://www.ngncapital.com/

NGN Capital

CONTACT: Kenneth Abramowitz of NGN Capital, +1-212-351-5001, orkabramowitz@ngncapital.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES